Literature DB >> 23989023

Assessment of external lymphedema in patients with head and neck cancer: a comparison of four scales.

Jie Deng1, Sheila H Ridner, Mary S Dietrich, Nancy Wells, Barbara A Murphy.   

Abstract

PURPOSE/
OBJECTIVES: To compare available grading and staging scales that measure external lymphedema in patients with head and neck cancer (HNC) and to assess problems and gaps related to these tools.
DESIGN: Cross-sectional.
SETTING: A comprehensive cancer center in Tennessee. SAMPLE: 103 participants post-HNC treatment.
METHODS: Four scales were used to evaluate study participant external lymphedema status, including the Common Terminology Criteria for Adverse Events (CTCAE) Lymphedema Scale (version 3.0), American Cancer Society Lymphedema Scale, Stages of Lymphedema (Földi's Scale), and the CTCAE Fibrosis Scale (version 3.0). MAIN RESEARCH VARIABLES: Occurrence rate, severity of lymphedema, and components and descriptors of each scale.
FINDINGS: The prevalence and severity of external lymphedema differed based on the tools. Each tool had an identified limitation. Current theory postulates a continuum between lymphedema and fibrosis, but only the Földi's Scale adequately reflected that concept.
CONCLUSIONS: None of the available scales clearly captured all the important characteristics of external lymphedema in patients with HNC. A need exists to develop a clearly defined and validated scale of external lymphedema in the HNC population. IMPLICATIONS FOR NURSING: Oncology nurses should take an active role in addressing issues related to lymphedema assessment in patients post-HNC treatment; however, new assessment tools need to be developed for clinical use. KNOWLEDGE TRANSLATION: Early identification and accurate documentation of head and neck lymphedema are critically important to prevent lymphedema progress. However, existing grading criteria failed to capture important characteristics of external head and neck lymphedema. More research efforts need to be made to address this under-recognized issue.

Entities:  

Mesh:

Year:  2013        PMID: 23989023     DOI: 10.1188/13.ONF.501-506

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  6 in total

1.  Evaluation of CT Changes in the Head and Neck After Cancer Treatment: Development of a Measurement Tool.

Authors:  Joseph M Aulino; Elizabeth M Wulff-Burchfield; Mary S Dietrich; Sheila H Ridner; Kenneth J Niermann; Jie Deng; Bethany A Rhoten; Jennifer K Doersam; Lee Ann Jarrett; Kyle Mannion; Barbara A Murphy
Journal:  Lymphat Res Biol       Date:  2018-02       Impact factor: 2.589

2.  TOXICAN: a guide for grading dermatological adverse events of cancer treatments.

Authors:  L Peuvrel; J Cassecuel; C Bernier; G Quéreux; M Saint-Jean; M Le Moigne; C Frénard; A Khammari; B Dréno
Journal:  Support Care Cancer       Date:  2018-03-12       Impact factor: 3.603

3.  Lymphedema outcomes in patients with head and neck cancer.

Authors:  Brad G Smith; Katherine A Hutcheson; Leila G Little; Roman J Skoracki; David I Rosenthal; Stephen Y Lai; Jan S Lewin
Journal:  Otolaryngol Head Neck Surg       Date:  2014-11-11       Impact factor: 3.497

Review 4.  Recent progress in the treatment and prevention of cancer-related lymphedema.

Authors:  Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier
Journal:  CA Cancer J Clin       Date:  2014-11-19       Impact factor: 508.702

5.  Translation and adaptation to Brazilian Portuguese of the Lymphedema Rating Scale in Head and Neck Cancer.

Authors:  Débora Dos Santos Queija; Lica Arakawa-Sugueno; Bruna Mello Chamma; Marco Aurélio Vamondes Kulcsar; Rogério Aparecido Dedivitis
Journal:  Einstein (Sao Paulo)       Date:  2017-12-18

6.  Translation and adaptation of the Radiotherapy Edema Rating Scale to Brazilian Portuguese.

Authors:  Débora Dos Santos Queija; Lica Arakawa-Sugueno; Bruna Mello Chamma; Marco Aurélio Vamondes Kulcsar; Rogério Aparecido Dedivitis
Journal:  Braz J Otorhinolaryngol       Date:  2017-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.